- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 156
Eureka proclaims fund's first close
Italian tech transfer fund Eureka has attracted an initial $44.9m from LPs including ItaTech as well as Umbra and Saes to invest in spinouts from domestic institutions.
Jul 30, 2020Yissum spinouts haul in $79m in H1 2020
Funding for HUJ spinouts remained stable during the first six months of 2020 as the Israeli VC sector showed signs of resilience amid Covid-19.
Jul 29, 2020Bright Peak ascends to $35m series A
Drug protein discovery company Bright Peak hopes to deliver conjugated cancer immunotherapies based on an ETH Zürich-invented platform.
Jul 29, 2020Kentucky trio target state-wide commercialisation
University of Louisville, University of Kentucky and Kentucky Science and Technology will extend their tech transfer expertise to other local institutions.
Jul 29, 2020Praxis Precision works out $110m series C1
Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.
Jul 29, 2020Gentex absorbs Vaporsens
University of Utah spinout Vaporsens has been acquired by Gentex for $10.5m after the corporate had already supplied $3m in equity financing.
Jul 29, 2020Daily deal net: July 28, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Jul 28, 2020Enthera enters $32.8m series A round
Enthera Pharmaceuticals was co-founded by faculty from University of Milan and is using stem cells to treat autoimmune disorders.
Jul 28, 2020CureVac files for IPO
CureVac has filed for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.
Jul 28, 2020MBX Biosciences extrapolates $34.6m
IU Philanthropic Venture Fund returned for a series A round expected to help MBX identify clinical-stage peptides for rare endocrine genetic diseases.
Jul 28, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits our membership, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


